top of page

NCI-2022-02453

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer


Doctors are conducting a study to test the safety and effectiveness of a new medicine called DAN-222 in treating a type of breast cancer called metastatic breast cancer. The study is a dose-escalation study, which means that patients will receive increasing amounts of DAN-222 over time to determine the maximum safe and effective dose. The study will also evaluate the pharmacology of the medicine, which means how it works in the body and how the body processes it. Patients in the study will have metastatic breast cancer. The goal of the study is to determine if DAN-222 is safe and effective in treating this type of breast cancer. By testing different doses of DAN-222 and monitoring its effects on patients, doctors hope to learn more about how the medicine works and whether it could be a new treatment option for patients with metastatic breast cancer.

Metastatic: a cancer that has spread from its original location or organ to other parts of the body.

For more information about the trial, click the link below:

NCI-2022-02453

Clinical Trial Site: Mount Sinai


To see all available clinical trials click here.

Recent Posts

See All

NCI-2023-06503

An open-label, single-arm, Phase 1b/2 study to investigate the safety, efficacy and pharmacokinetics of LS301-IT in female patients undergoing partial mastectomy and sentinel lymph node biopsy (SLNB)

NCI-2022-07265

EAY191-N2 Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1 A ComboMATC

NCI-2018-02927

Phase I/II Trial of Leflunomide in Women with Previously Treated Metastatic Triple Negative Cancer This is a research study that has two parts, or "phases." The study is looks at a medicine called Lef

Comments


bottom of page